Eledon Pharmaceuticals reports narrowed Q2 loss; Advances tegoprubart across transplant programs
Company posted a net loss of $11.2 million, or $0.13 per basic common share IRVINE: Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) on Thursday reported a significantly reduced net loss for the second quarter of 2025, alongside key clinical and operational milestones…